First, we performed MTT assays in a 6×6 dose matrix format to test for any synergistic activity between BCL2 inhibitors and 2DG in either ER+ MCF7-pSFFV or TNBC HDQ-P1 breast cancer cells. This evidence concerns the gene BCL2 and breast cancer.